Post navigation

Targeting Chronic Hepatitis B Infections Affecting More Than 240 Million People Worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has entered into a research collaboration agreement with Georgia State University Research Foundation …Continue reading →

Babies born to mothers with chronic hepatitis B virus (HBV) and high HBV DNA levels remain at risk for HBV transmission and development of chronic infection despite routine immunoprophylaxis at the time of birth. Treatment of pregnant women with an …Continue reading →

— Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade — FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted …Continue reading →